newsfilter
← Latest News
Business Wire·

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

Pivotal Phase 2 trial of RP-A501 for Danon disease progressing with dosing reinitiated First patient dosing in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy anticipated in